Blaise F.D. Bourgeois, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticonvulsants | 64 | 2018 | 1923 | 4.170 |
Why?
|
| Epilepsy | 67 | 2014 | 3326 | 2.720 |
Why?
|
| Epilepsies, Partial | 15 | 2018 | 435 | 1.030 |
Why?
|
| Fructose | 12 | 2005 | 284 | 0.820 |
Why?
|
| Carbamazepine | 16 | 2005 | 224 | 0.810 |
Why?
|
| Cyclohexanecarboxylic Acids | 8 | 2004 | 140 | 0.770 |
Why?
|
| Amines | 8 | 2004 | 280 | 0.720 |
Why?
|
| Epilepsy, Generalized | 7 | 2018 | 181 | 0.680 |
Why?
|
| Valproic Acid | 10 | 2003 | 443 | 0.600 |
Why?
|
| Seizures | 19 | 2018 | 3000 | 0.550 |
Why?
|
| Phenytoin | 10 | 2004 | 190 | 0.510 |
Why?
|
| Magnetoencephalography | 8 | 2013 | 642 | 0.460 |
Why?
|
| Phenobarbital | 11 | 2012 | 192 | 0.450 |
Why?
|
| Anthropometry | 1 | 2017 | 1343 | 0.410 |
Why?
|
| gamma-Aminobutyric Acid | 10 | 2004 | 1143 | 0.370 |
Why?
|
| Electroencephalography | 27 | 2014 | 6317 | 0.360 |
Why?
|
| Epilepsy, Absence | 4 | 2018 | 50 | 0.350 |
Why?
|
| Epilepsy, Temporal Lobe | 6 | 2014 | 390 | 0.350 |
Why?
|
| Propylene Glycols | 6 | 1998 | 91 | 0.340 |
Why?
|
| Prader-Willi Syndrome | 1 | 2010 | 79 | 0.340 |
Why?
|
| Triazines | 8 | 2004 | 312 | 0.320 |
Why?
|
| Body Composition | 1 | 2017 | 2461 | 0.290 |
Why?
|
| Drug Interactions | 14 | 2013 | 1420 | 0.270 |
Why?
|
| Temporal Lobe | 5 | 2010 | 1728 | 0.270 |
Why?
|
| Child | 68 | 2018 | 80891 | 0.270 |
Why?
|
| Perilymph | 1 | 2005 | 50 | 0.250 |
Why?
|
| Primidone | 6 | 1998 | 9 | 0.240 |
Why?
|
| Landau-Kleffner Syndrome | 1 | 2004 | 10 | 0.240 |
Why?
|
| Middle Ear Ventilation | 1 | 2005 | 101 | 0.230 |
Why?
|
| Labyrinth Diseases | 1 | 2005 | 151 | 0.230 |
Why?
|
| Fistula | 1 | 2005 | 213 | 0.220 |
Why?
|
| Clinical Trials as Topic | 12 | 2007 | 8051 | 0.210 |
Why?
|
| Functional Laterality | 5 | 2014 | 2268 | 0.210 |
Why?
|
| Cognition Disorders | 5 | 2014 | 3985 | 0.210 |
Why?
|
| Spasms, Infantile | 4 | 2012 | 301 | 0.200 |
Why?
|
| Triazoles | 3 | 2014 | 904 | 0.200 |
Why?
|
| Acetates | 8 | 2004 | 317 | 0.180 |
Why?
|
| Adolescent | 49 | 2017 | 89184 | 0.180 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 13020 | 0.170 |
Why?
|
| Phenylcarbamates | 6 | 1998 | 38 | 0.170 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 1999 | 54 | 0.170 |
Why?
|
| Cognition | 6 | 2014 | 7075 | 0.160 |
Why?
|
| Humans | 113 | 2018 | 768393 | 0.160 |
Why?
|
| Signal Processing, Computer-Assisted | 6 | 2009 | 1496 | 0.160 |
Why?
|
| Epilepsy, Complex Partial | 3 | 2007 | 59 | 0.150 |
Why?
|
| Vigabatrin | 5 | 2012 | 88 | 0.150 |
Why?
|
| Benzodiazepines | 2 | 2014 | 1139 | 0.150 |
Why?
|
| Methylphenidate | 2 | 2014 | 491 | 0.150 |
Why?
|
| Drug Therapy, Combination | 13 | 2014 | 6318 | 0.150 |
Why?
|
| Medication Errors | 1 | 2004 | 784 | 0.150 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2018 | 85 | 0.140 |
Why?
|
| Optical Devices | 1 | 2017 | 35 | 0.140 |
Why?
|
| Plethysmography | 1 | 2017 | 173 | 0.140 |
Why?
|
| Child, Preschool | 29 | 2014 | 42650 | 0.140 |
Why?
|
| Drug Resistance | 4 | 2018 | 1595 | 0.140 |
Why?
|
| Child Behavior | 2 | 2002 | 865 | 0.130 |
Why?
|
| Brain Chemistry | 5 | 1994 | 962 | 0.130 |
Why?
|
| Phenylethylmalonamide | 3 | 1983 | 3 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2014 | 10776 | 0.120 |
Why?
|
| Cerebral Cortex | 9 | 2012 | 5831 | 0.110 |
Why?
|
| Biological Clocks | 2 | 2010 | 321 | 0.110 |
Why?
|
| Hemispherectomy | 1 | 2014 | 41 | 0.110 |
Why?
|
| Malformations of Cortical Development | 2 | 2014 | 176 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 2 | 2014 | 1181 | 0.110 |
Why?
|
| Malonates | 2 | 1983 | 43 | 0.110 |
Why?
|
| Action Potentials | 2 | 2013 | 1838 | 0.110 |
Why?
|
| Mental Processes | 1 | 1994 | 247 | 0.110 |
Why?
|
| Sodium Channels | 2 | 2008 | 341 | 0.110 |
Why?
|
| Amphetamine | 1 | 2014 | 225 | 0.110 |
Why?
|
| Water | 1 | 1999 | 1418 | 0.110 |
Why?
|
| Half-Life | 7 | 2008 | 650 | 0.100 |
Why?
|
| Treatment Outcome | 24 | 2014 | 65379 | 0.100 |
Why?
|
| Syndrome | 4 | 2013 | 3275 | 0.100 |
Why?
|
| Anti-Anxiety Agents | 1 | 1995 | 405 | 0.100 |
Why?
|
| Laughter | 1 | 2011 | 19 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2014 | 3743 | 0.100 |
Why?
|
| Sleep Stages | 1 | 1996 | 705 | 0.100 |
Why?
|
| Infant | 21 | 2014 | 36510 | 0.100 |
Why?
|
| Hemifacial Spasm | 1 | 2011 | 24 | 0.100 |
Why?
|
| Drug Administration Schedule | 7 | 2005 | 4859 | 0.090 |
Why?
|
| Drug Chronotherapy | 1 | 2010 | 10 | 0.090 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 1752 | 0.090 |
Why?
|
| Male | 49 | 2017 | 364902 | 0.090 |
Why?
|
| Adult | 38 | 2018 | 223640 | 0.090 |
Why?
|
| Cerebrum | 1 | 2012 | 132 | 0.090 |
Why?
|
| Female | 55 | 2017 | 397089 | 0.090 |
Why?
|
| Trisomy | 1 | 2012 | 260 | 0.090 |
Why?
|
| Niacinamide | 2 | 1983 | 418 | 0.090 |
Why?
|
| Hypothalamic Diseases | 1 | 2011 | 134 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2012 | 640 | 0.080 |
Why?
|
| Acetamides | 1 | 2011 | 260 | 0.080 |
Why?
|
| Epilepsy, Frontal Lobe | 1 | 2009 | 24 | 0.080 |
Why?
|
| Nipecotic Acids | 4 | 2004 | 36 | 0.080 |
Why?
|
| Hamartoma | 1 | 2011 | 236 | 0.080 |
Why?
|
| Equipment Design | 1 | 2017 | 3529 | 0.080 |
Why?
|
| Nerve Net | 2 | 2012 | 2362 | 0.080 |
Why?
|
| Polysomnography | 1 | 1996 | 1865 | 0.080 |
Why?
|
| Learning | 1 | 1998 | 1761 | 0.080 |
Why?
|
| Mental Disorders | 2 | 2007 | 6876 | 0.070 |
Why?
|
| Moyamoya Disease | 1 | 2011 | 274 | 0.070 |
Why?
|
| Neurotoxins | 1 | 1988 | 241 | 0.070 |
Why?
|
| Drug Monitoring | 2 | 2008 | 964 | 0.070 |
Why?
|
| Mephenytoin | 1 | 1986 | 3 | 0.070 |
Why?
|
| Hydantoins | 1 | 1986 | 12 | 0.070 |
Why?
|
| Hypothalamus | 1 | 2011 | 1004 | 0.070 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2009 | 229 | 0.070 |
Why?
|
| Myoclonic Epilepsy, Juvenile | 1 | 2005 | 13 | 0.070 |
Why?
|
| Frontal Lobe | 2 | 2009 | 1428 | 0.060 |
Why?
|
| Piracetam | 4 | 2010 | 88 | 0.060 |
Why?
|
| Biological Availability | 3 | 2008 | 392 | 0.060 |
Why?
|
| Neurogenesis | 1 | 2012 | 864 | 0.060 |
Why?
|
| Young Adult | 12 | 2017 | 60049 | 0.060 |
Why?
|
| Nervous System Malformations | 1 | 2007 | 244 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2011 | 950 | 0.060 |
Why?
|
| Consensus | 1 | 2014 | 3212 | 0.060 |
Why?
|
| Brain Mapping | 5 | 2012 | 6740 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2013 | 10377 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2014 | 2693 | 0.060 |
Why?
|
| Pediatrics | 3 | 2010 | 3624 | 0.060 |
Why?
|
| Choristoma | 1 | 2005 | 205 | 0.060 |
Why?
|
| Retrospective Studies | 16 | 2014 | 81801 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2460 | 0.050 |
Why?
|
| Electroshock | 4 | 1994 | 120 | 0.050 |
Why?
|
| Age Factors | 9 | 2006 | 18471 | 0.050 |
Why?
|
| Language | 1 | 2012 | 1558 | 0.050 |
Why?
|
| Cerebral Ventricles | 1 | 2005 | 550 | 0.050 |
Why?
|
| Algorithms | 3 | 2014 | 14154 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2004 | 246 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2010 | 12456 | 0.050 |
Why?
|
| Poisoning | 1 | 2004 | 252 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2011 | 1515 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 455 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2014 | 36849 | 0.050 |
Why?
|
| Risperidone | 1 | 2004 | 383 | 0.050 |
Why?
|
| Pentylenetetrazole | 3 | 1988 | 72 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2014 | 2862 | 0.050 |
Why?
|
| Isoniazid | 1 | 1982 | 288 | 0.050 |
Why?
|
| Craniocerebral Trauma | 1 | 2005 | 495 | 0.050 |
Why?
|
| Brain Diseases | 3 | 2002 | 1552 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 20224 | 0.040 |
Why?
|
| Thiazines | 1 | 2000 | 38 | 0.040 |
Why?
|
| Infant, Newborn, Diseases | 2 | 1983 | 591 | 0.040 |
Why?
|
| Antipsychotic Agents | 2 | 2004 | 3080 | 0.040 |
Why?
|
| Drug Industry | 1 | 2007 | 793 | 0.040 |
Why?
|
| Pregnanolone | 1 | 2000 | 67 | 0.040 |
Why?
|
| Sclerosis | 2 | 1998 | 212 | 0.040 |
Why?
|
| Kainic Acid | 1 | 2000 | 203 | 0.040 |
Why?
|
| Follow-Up Studies | 9 | 2014 | 39407 | 0.040 |
Why?
|
| Succinimides | 1 | 1999 | 83 | 0.040 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2009 | 1489 | 0.040 |
Why?
|
| Carbonic Anhydrases | 1 | 2000 | 108 | 0.040 |
Why?
|
| Atrophy | 1 | 2004 | 1648 | 0.040 |
Why?
|
| Drug Approval | 3 | 2004 | 818 | 0.040 |
Why?
|
| Theta Rhythm | 1 | 2001 | 222 | 0.040 |
Why?
|
| Acidosis | 1 | 2001 | 271 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1999 | 313 | 0.040 |
Why?
|
| Intelligence | 1 | 1983 | 929 | 0.040 |
Why?
|
| Isoxazoles | 3 | 2004 | 233 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2013 | 1727 | 0.040 |
Why?
|
| Middle Aged | 13 | 2017 | 223491 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 2056 | 0.040 |
Why?
|
| Intelligence Tests | 2 | 2007 | 505 | 0.040 |
Why?
|
| Reaction Time | 3 | 2004 | 2103 | 0.040 |
Why?
|
| Electric Stimulation Therapy | 2 | 2002 | 636 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2002 | 628 | 0.040 |
Why?
|
| Time Factors | 7 | 2014 | 40272 | 0.040 |
Why?
|
| Causality | 1 | 2004 | 1255 | 0.040 |
Why?
|
| Mice, Inbred ICR | 2 | 1988 | 363 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2006 | 2258 | 0.030 |
Why?
|
| Kinetics | 4 | 1986 | 6333 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 2006 | 916 | 0.030 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 15939 | 0.030 |
Why?
|
| Mice, Inbred Strains | 3 | 1983 | 1769 | 0.030 |
Why?
|
| Calcium Channels | 1 | 2000 | 624 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 4414 | 0.030 |
Why?
|
| Brain | 7 | 2014 | 27454 | 0.030 |
Why?
|
| Benzodiazepinones | 1 | 1995 | 50 | 0.030 |
Why?
|
| Biopharmaceutics | 1 | 1995 | 23 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1999 | 1390 | 0.030 |
Why?
|
| Aged | 7 | 2017 | 171562 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15881 | 0.030 |
Why?
|
| Hippocampus | 2 | 2000 | 3784 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2001 | 1010 | 0.030 |
Why?
|
| Neurosurgical Procedures | 2 | 2002 | 2097 | 0.030 |
Why?
|
| Neuropsychological Tests | 3 | 2014 | 7145 | 0.030 |
Why?
|
| Intestinal Absorption | 1 | 1995 | 400 | 0.030 |
Why?
|
| Child Behavior Disorders | 1 | 1998 | 813 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1979 | 1097 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 4250 | 0.030 |
Why?
|
| Adolescent Behavior | 1 | 2002 | 1190 | 0.030 |
Why?
|
| Infant, Newborn | 7 | 2008 | 26411 | 0.030 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2014 | 187 | 0.030 |
Why?
|
| Radiosurgery | 1 | 2002 | 1346 | 0.030 |
Why?
|
| Psychosurgery | 1 | 1993 | 86 | 0.030 |
Why?
|
| Software | 1 | 2007 | 4453 | 0.030 |
Why?
|
| Amygdala | 1 | 2000 | 1382 | 0.030 |
Why?
|
| Drug Synergism | 3 | 1994 | 1762 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 3722 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2004 | 3579 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1994 | 213 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 1993 | 624 | 0.020 |
Why?
|
| Electrodes, Implanted | 2 | 2009 | 841 | 0.020 |
Why?
|
| Diethylcarbamazine | 1 | 2010 | 23 | 0.020 |
Why?
|
| Recurrence | 2 | 1995 | 8506 | 0.020 |
Why?
|
| Vomiting | 1 | 2014 | 655 | 0.020 |
Why?
|
| Models, Biological | 1 | 2007 | 9493 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2012 | 619 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6670 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2004 | 6277 | 0.020 |
Why?
|
| Mice | 9 | 1994 | 82017 | 0.020 |
Why?
|
| Arousal | 1 | 1996 | 1183 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2005 | 8075 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 5538 | 0.020 |
Why?
|
| Placebos | 1 | 1994 | 1668 | 0.020 |
Why?
|
| Comorbidity | 2 | 2007 | 10588 | 0.020 |
Why?
|
| Wakefulness | 1 | 1996 | 1283 | 0.020 |
Why?
|
| Risk Factors | 3 | 2002 | 74962 | 0.020 |
Why?
|
| Ethosuximide | 1 | 1988 | 9 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2004 | 3279 | 0.020 |
Why?
|
| Cerebral Revascularization | 1 | 2011 | 263 | 0.020 |
Why?
|
| Suppositories | 1 | 1987 | 16 | 0.020 |
Why?
|
| Research Design | 2 | 2006 | 6210 | 0.020 |
Why?
|
| Quality of Life | 2 | 2007 | 13503 | 0.020 |
Why?
|
| Tablets, Enteric-Coated | 1 | 1987 | 20 | 0.020 |
Why?
|
| Cortical Synchronization | 1 | 2007 | 78 | 0.020 |
Why?
|
| Internationality | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 1993 | 1058 | 0.020 |
Why?
|
| Physical Examination | 1 | 1993 | 1262 | 0.020 |
Why?
|
| Scalp | 1 | 2009 | 391 | 0.020 |
Why?
|
| Prospective Studies | 6 | 2014 | 54920 | 0.020 |
Why?
|
| Animals | 10 | 2002 | 169337 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1986 | 363 | 0.020 |
Why?
|
| International Agencies | 1 | 2006 | 245 | 0.020 |
Why?
|
| United States Food and Drug Administration | 2 | 2004 | 1672 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 2931 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2009 | 1743 | 0.010 |
Why?
|
| Predictive Value of Tests | 3 | 2007 | 15455 | 0.010 |
Why?
|
| Neurofibromatosis 1 | 1 | 2009 | 561 | 0.010 |
Why?
|
| Administration, Oral | 2 | 1994 | 4039 | 0.010 |
Why?
|
| Biotransformation | 1 | 1984 | 166 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 2106 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2010 | 2363 | 0.010 |
Why?
|
| Reoperation | 1 | 2014 | 4341 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1979 | 3681 | 0.010 |
Why?
|
| Kidney | 1 | 1979 | 7064 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 187 | 0.010 |
Why?
|
| Bicuculline | 1 | 1983 | 96 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 1983 | 258 | 0.010 |
Why?
|
| United States | 4 | 2012 | 73150 | 0.010 |
Why?
|
| Electrodes | 1 | 2005 | 617 | 0.010 |
Why?
|
| Seizures, Febrile | 1 | 1983 | 109 | 0.010 |
Why?
|
| Diet | 1 | 2000 | 8090 | 0.010 |
Why?
|
| Evidence-Based Medicine | 2 | 2004 | 3707 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 1364 | 0.010 |
Why?
|
| Cerebral Infarction | 1 | 2006 | 975 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 1515 | 0.010 |
Why?
|
| Reference Values | 1 | 2008 | 4941 | 0.010 |
Why?
|
| Artifacts | 1 | 2009 | 1930 | 0.010 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2001 | 91 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1993 | 10117 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 2001 | 440 | 0.010 |
Why?
|
| Bicarbonates | 1 | 2001 | 292 | 0.010 |
Why?
|
| Verbal Behavior | 1 | 2001 | 336 | 0.010 |
Why?
|
| Vagus Nerve | 1 | 2002 | 460 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 2006 | 684 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 710 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2708 | 0.010 |
Why?
|
| Length of Stay | 1 | 1993 | 6519 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1979 | 187 | 0.010 |
Why?
|
| Aggression | 1 | 2004 | 750 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 1993 | 3541 | 0.010 |
Why?
|
| Observer Variation | 1 | 2005 | 2623 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2000 | 24318 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1998 | 134 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1988 | 1664 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 1979 | 361 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 1516 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2007 | 6034 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 1795 | 0.010 |
Why?
|
| Cues | 1 | 2001 | 884 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2000 | 8731 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1979 | 1502 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 2001 | 2004 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2006 | 2653 | 0.010 |
Why?
|
| Child Development | 1 | 2006 | 2334 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 1979 | 756 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 7242 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2010 | 4875 | 0.010 |
Why?
|
| Creatinine | 1 | 1979 | 1915 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2001 | 1783 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1994 | 366 | 0.010 |
Why?
|
| Videotape Recording | 1 | 1993 | 336 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 41795 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 14737 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 1979 | 2226 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 12092 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1998 | 3781 | 0.000 |
Why?
|
| Protein Binding | 1 | 1999 | 9343 | 0.000 |
Why?
|
| Acute Kidney Injury | 1 | 1979 | 1943 | 0.000 |
Why?
|
| Immunosuppressive Agents | 1 | 1978 | 4209 | 0.000 |
Why?
|
| Prognosis | 1 | 2006 | 30022 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1994 | 6350 | 0.000 |
Why?
|
| Disease Progression | 1 | 2000 | 13646 | 0.000 |
Why?
|
| Body Weight | 1 | 1994 | 4629 | 0.000 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1978 | 3777 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1998 | 9063 | 0.000 |
Why?
|
| Chlorambucil | 1 | 1978 | 42 | 0.000 |
Why?
|
| Hematologic Diseases | 1 | 1978 | 499 | 0.000 |
Why?
|
| Cyclophosphamide | 1 | 1978 | 2226 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1993 | 9198 | 0.000 |
Why?
|
| Risk | 1 | 1978 | 9636 | 0.000 |
Why?
|
| Neoplasms | 1 | 1978 | 22385 | 0.000 |
Why?
|